Abbott Laboratories
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | $17.30B | $35.80B | $9.80B |
| FY2022 | $14.52B | $36.69B | $9.88B |
| FY2023 | $13.60B | $38.60B | $6.90B |
| FY2024 | $12.63B | $47.66B | $7.62B |
| FY2025 | $9.90B | $52.13B | $8.52B |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | $17.30B | $35.80B | $9.80B |
| FY2022 | $14.52B | $36.69B | $9.88B |
| FY2023 | $13.60B | $38.60B | $6.90B |
| FY2024 | $12.63B | $47.66B | $7.62B |
| FY2025 | $9.90B | $52.13B | $8.52B |